180 related articles for article (PubMed ID: 17657816)
1. Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
Hepatology; 2007 Nov; 46(5):1357-64. PubMed ID: 17657816
[TBL] [Abstract][Full Text] [Related]
2. Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy.
Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
J Med Virol; 2011 Jun; 83(6):1016-22. PubMed ID: 21503914
[TBL] [Abstract][Full Text] [Related]
3. Long-term interferon monotherapy reduces the risk of HCV-associated hepatocellular carcinoma.
Takeyasu M; Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2012 Aug; 84(8):1199-207. PubMed ID: 22711347
[TBL] [Abstract][Full Text] [Related]
4. Amino acid substitutions in the hepatitis C Virus core region and lipid metabolism are associated with hepatocarcinogenesis in nonresponders to interferon plus ribavirin combination therapy.
Seko Y; Akuta N; Suzuki F; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
Intervirology; 2013; 56(1):13-21. PubMed ID: 22907167
[TBL] [Abstract][Full Text] [Related]
5. Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha-fetoprotein in patients without hepatocellular carcinoma.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2008 Aug; 80(8):1354-62. PubMed ID: 18551609
[TBL] [Abstract][Full Text] [Related]
6. Virological and biochemical features in elderly HCV patients with hepatocellular carcinoma: amino acid substitutions in HCV core region as predictor of mortality after first treatment.
Ogura S; Akuta N; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Kobayashi M; Suzuki F; Suzuki Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
Intervirology; 2009; 52(4):179-88. PubMed ID: 19546575
[TBL] [Abstract][Full Text] [Related]
7. Viral decline over 48h and HCV amino acid mutations are related to efficacy of PEG-IFN/ribavirin.
Miyasaka A; Kumagai I; Abe K; Suzuki K
Hepatogastroenterology; 2012 May; 59(115):794-9. PubMed ID: 22020909
[TBL] [Abstract][Full Text] [Related]
8. Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis.
Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Hara T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
Hepatology; 2012 Dec; 56(6):2134-41. PubMed ID: 22806754
[TBL] [Abstract][Full Text] [Related]
9. Association between mutations in the core region of hepatitis C virus genotype 1 and hepatocellular carcinoma development.
Nakamoto S; Imazeki F; Fukai K; Fujiwara K; Arai M; Kanda T; Yonemitsu Y; Yokosuka O
J Hepatol; 2010 Jan; 52(1):72-8. PubMed ID: 19910070
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2008 Aug; 80(8):1363-9. PubMed ID: 18551610
[TBL] [Abstract][Full Text] [Related]
11. Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus.
Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
J Med Virol; 2009 Jun; 81(6):1032-9. PubMed ID: 19382270
[TBL] [Abstract][Full Text] [Related]
12. Impact of amino acid substitutions in the hepatitis C virus genotype 1b core region on liver steatosis and hepatic oxidative stress in patients with chronic hepatitis C.
Tachi Y; Katano Y; Honda T; Hayashi K; Ishigami M; Itoh A; Hirooka Y; Nakano I; Samejima Y; Goto H
Liver Int; 2010 Apr; 30(4):554-9. PubMed ID: 19951380
[TBL] [Abstract][Full Text] [Related]
13. Amino acid substitutions in the hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by all-oral direct-acting antiviral regimens.
Ogata F; Akuta N; Kobayashi M; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Kobayashi M; Saitoh S; Suzuki Y; Suzuki F; Arase Y; Ikeda K; Kumada H
J Med Virol; 2018 Jun; 90(6):1087-1093. PubMed ID: 29427443
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus: multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival.
Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
Scand J Gastroenterol; 2005 Jun; 40(6):688-96. PubMed ID: 16036529
[TBL] [Abstract][Full Text] [Related]
15. α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C.
Asahina Y; Tsuchiya K; Nishimura T; Muraoka M; Suzuki Y; Tamaki N; Yasui Y; Hosokawa T; Ueda K; Nakanishi H; Itakura J; Takahashi Y; Kurosaki M; Enomoto N; Nakagawa M; Kakinuma S; Watanabe M; Izumi N
Hepatology; 2013 Oct; 58(4):1253-62. PubMed ID: 23564522
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and anticarcinogenic activity of ribavirin combination therapy for hepatitis C virus-related compensated cirrhosis.
Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
Intervirology; 2013; 56(1):37-45. PubMed ID: 23037768
[TBL] [Abstract][Full Text] [Related]
17. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
[TBL] [Abstract][Full Text] [Related]
18. Impact of Mutations at Amino Acid 70 in Hepatitis C Virus (HCV) Genotype 1b Core Region on Hepatocarcinogenesis following Eradication of HCV RNA.
Akuta N; Suzuki F; Kobayashi M; Sezaki H; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
J Clin Microbiol; 2015 Sep; 53(9):3039-41. PubMed ID: 26135874
[TBL] [Abstract][Full Text] [Related]
19. Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN-resistant cases with hepatocyte steatosis.
Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
J Med Virol; 2005 Apr; 75(4):550-8. PubMed ID: 15714492
[TBL] [Abstract][Full Text] [Related]
20. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon.
Di Bisceglie AM; Thompson J; Smith-Wilkaitis N; Brunt EM; Bacon BR
Hepatology; 2001 Mar; 33(3):704-7. PubMed ID: 11230751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
